FindTrial
Sign In

Maternal Mental Health (MAMA) Study. Short time estrogen as a candidate strategy to prevent postpartum depression in a high-risk group

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518028-63-00
Acronym
2020-001592-33
Enrollment
220
Registered
2024-10-08
Start date
2024-10-08
Completion date
Unknown
Last updated
2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perinatal depression with postpartum onset

Brief summary

Clinical depression according to DSM-V criteria. Between 2 weeks and 6 months postpartum

Interventions

DRUGVivelle Dot 100 mikrogram/24 timer
DRUGdepotplaster.
DRUGPlacebo is Comfeel Plus Transparent from Coloplast. The Comfeel Plus Transparent is a thin and flexible hydrocolloid dressing. https://www.coloplast.dk/comfeel-plus-transparent-da-dk.aspx#section=product-description_3

Sponsors

Rigshospitalet
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Clinical depression according to DSM-V criteria. Between 2 weeks and 6 months postpartum—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026